Penn Researchers Identify Potential New Therapeutic
Approach for Sickle Cell Disease
(Philadelphia, PA) – University of Pennsylvania School of Medicine
researchers have identified an embryonic protein present
in all humans that, when produced in mice, dramatically
reduces symptoms of sickle cell disease. The discovery
raises the possibility of new treatment options for
sickle cell patients, say co-authors J. Eric
Russell, MD, Assistant Professor
of Medicine and Pediatrics, and Zhenning He,
research specialist, Department of Medicine. The research
appears in the April issue of Nature Medicine.
Sickle cell disease is an inherited, red-blood-cell
disorder in humans characterized by chronic anemia,
episodes of severe pain, and premature death. It is
caused by an error in one of the genes that produces
hemoglobin, an iron-protein component contained within
the red blood cells that carry oxygen to body tissues.
The defective gene directs production of abnormal hemoglobin,
resulting in deformed (sickle-shaped) red blood cells
that block small blood vessels. This results in pain,
stroke, heart attacks, kidney failure, and premature
death in adults and children.
Although there is no cure for sickle cell disease, treatments
are available, including administration of the anti-cancer
drug hydroxyurea, blood transfusions, and bone marrow
transplantation. Hydroxyurea is widely used to reactivate
the production of gamma globin, which substitutes for
the defective component of hemoglobin, called beta globin.
Although this approach does not cure the disease, it
frequently results in a lessening of symptoms.
Russell and He used a novel approach to modify alpha
globin, the other major component of hemoglobin. This
could help patients who have responded poorly to conventional
hydroxyurea treatment or who are unable to tolerate
its side effects. Conceivably, therapies resulting from
this study could be combined with standard treatments
to further reduce disease severity.
The researchers genetically engineered mice with sickle
cell disease to produce zeta globin, the embryonic form
of the human alpha chain of hemoglobin. Unlike mice
with sickle cell disease, the genetically altered mice
had normal blood counts and were no longer anemic. In
addition, the life span of their red blood cells was
extended almost five-fold to normal levels. Sickled
cells did not appear in the blood of the mice and kidney
“Our work demonstrates a novel therapeutic approach
that reverses the disease process in mice with sickle
cell disease,” says Russell. “Clearly, there
is much more work to be done before this approach can
be tested in humans. Nevertheless, targeted reactivation
of zeta globin, either alone or in combination with
existing treatments, anticipates therapies in humans
that are more flexible and potentially more effective
than those that are currently available for this devastating
Sickle cell disease affects millions of people throughout
the world. It is the most common inherited genetic disease
in the United States, affecting approximately 72,000
people. The disease occurs in about one in every 500
African-American births and about one in every 1,000-1,400
Hispanic American births.
Additionally, approximately two million Americans, including
1 in 12 African Americans, have sickle cell trait. They
do not suffer from the disease itself, but have the
potential to pass the disease on to their children.
The research was supported in part by grants from the
National Institutes of Health. The authors have no competing
financial interests in this research. Dr. Russell can
be reached at 215-590-3880 or email@example.com.
a printer friendly version of this release, click
PENN Medicine is a $2.5 billion enterprise dedicated
to the related missions of medical education, biomedical
research, and high-quality patient care. PENN Medicine
consists of the University of Pennsylvania School of
Medicine (founded in 1765 as the nation’s first
medical school) and the University of Pennsylvania Health
System (created in 1993 as the nation’s first
integrated academic health system).
Penn’s School of Medicine is ranked #2 in the
nation for receipt of NIH research funds; and ranked
#4 in the nation in U.S. News & World Report’s
most recent ranking of top research-oriented medical
schools. Supporting 1,400 fulltime faculty and 700 students,
the School of Medicine is recognized worldwide for its
superior education and training of the next generation
of physician-scientists and leaders of academic medicine.
Penn Health System consists of four hospitals (including
its flagship Hospital of the University of Pennsylvania,
consistently rated one of the nation’s “Honor
Roll” hospitals by U.S. News & World Report),
a faculty practice plan, a primary-care provider network,
three multispecialty satellite facilities, and home
health care and hospice.
Penn Medicine is one of the world's leading academic medical centers, dedicated to the related missions of medical education, biomedical research, and excellence in patient care. Penn Medicine consists of the Raymond and Ruth Perelman School of Medicine at the University of Pennsylvania (founded in 1765 as the nation's first medical school) and the University of Pennsylvania Health System, which together form a $6.7 billion enterprise.
The Perelman School of Medicine has been ranked among the top five medical schools in the United States for the past 20 years, according to U.S. News & World Report's survey of research-oriented medical schools. The School is consistently among the nation's top recipients of funding from the National Institutes of Health, with $392 million awarded in the 2016 fiscal year.
The University of Pennsylvania Health System's patient care facilities include: The Hospital of the University of Pennsylvania and Penn Presbyterian Medical Center -- which are recognized as one of the nation's top "Honor Roll" hospitals by U.S. News & World Report -- Chester County Hospital; Lancaster General Health; Penn Wissahickon Hospice; and Pennsylvania Hospital -- the nation's first hospital, founded in 1751. Additional affiliated inpatient care facilities and services throughout the Philadelphia region include Good Shepherd Penn Partners, a partnership between Good Shepherd Rehabilitation Network and Penn Medicine.
Penn Medicine is committed to improving lives and health through a variety of community-based programs and activities. In fiscal year 2016, Penn Medicine provided $393 million to benefit our community.